Condition
Monocytic Leukemia
Total Trials
6
Recruiting
1
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
6Total
Not Applicable (1)
P 1 (3)
P 2 (2)
Trial Status
Completed3
Recruiting1
Active Not Recruiting1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT05282459Phase 1Completed
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
NCT07292272Phase 2Not Yet Recruiting
Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study
NCT06429449Phase 1Recruiting
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
NCT05871008Not ApplicableActive Not Recruiting
Integrated Actionable Aging Assessment for Cancer Patients Pilot
NCT04714372Phase 1Completed
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
NCT03613727Phase 2Completed
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Showing all 6 trials